Overview
Metastatic carcinoma involving the breast can lead to diverse clinical manifestations beyond the primary tumor site, including neurological complications such as carcinomatous hypertrophic pachymeningitis and ocular toxicities from chemotherapy.Diagnosis
Neurological Symptoms: Acute monocular visual loss, headache, elevated ESR and CRP levels may indicate carcinomatous hypertrophic pachymeningitis 1.
Imaging and Biopsies: Neuroimaging, dural biopsy, and breast biopsy are crucial for confirming metastatic involvement 1.
Ocular Pathology: Histopathologic examination of eyes and optic nerves can reveal vascular occlusions and nerve fiber layer infarctions in cases of chemotherapy-induced toxicity 2.Management
Corticosteroids: Effective for managing symptoms of carcinomatous hypertrophic pachymeningitis 1.
Chemotherapy Adjustments: Modify or discontinue high-dose carmustine and cisplatin to prevent severe ocular and neurological complications 2.
Supportive Care: Address specific complications such as visual rehabilitation and neurological support as needed 12.Special Populations
Comorbidities: High-dose chemotherapy regimens like carmustine and cisplatin pose significant risks, particularly in patients with pre-existing neurological or ocular conditions 2.Key Recommendations
Perform comprehensive imaging and biopsies when neurological symptoms suggest metastatic involvement to confirm diagnosis (Evidence: Moderate 1).
Initiate corticosteroid therapy for suspected carcinomatous hypertrophic pachymeningitis to alleviate symptoms (Evidence: Moderate 1).
Carefully monitor and adjust chemotherapy regimens, especially high-dose carmustine and cisplatin, to mitigate severe ocular and neurological toxicities (Evidence: Weak 2).References
1 Chan JW. Acute monocular visual loss in carcinomatous hypertrophic pachymeningitis mimicking giant cell arteritis. Rheumatology international 2006. link
2 Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. American journal of ophthalmology 2000. link00522-5)